To lead the next generation of genomic risk assessment testing using novel flow cytometry-based technologies and deliver faster, more accurate and less expensive results than sequencing
To commercialize highly accurate, low-cost genetic tests to assess risk for cancer and to assess their candidacy for certain therapies